Knee surgery pain relief gets a precision upgrade: new trial tests optimal dose
NCT ID NCT06942689
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests different volumes of liposomal bupivacaine, a long-acting painkiller, injected near the nerve in the thigh to numb the knee during surgery. The goal is to find the dose that provides good pain control while minimizing leg muscle weakness. Sixty-three adults having knee surgery will receive one of several volumes, and researchers will measure pain scores and muscle strength. The results could lead to more personalized and effective pain management after knee procedures.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- liposomal bupivacaine
- What this could lead to
- If successful, this could provide a precise dosing guide for longer-lasting pain relief after knee surgery with less muscle weakness.
- What could go wrong
- This is a small, early-phase trial (63 people) focused on dosing, not on proving long-term benefits. The results may not apply to all patients or surgeries.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPTIMAL VOLUME OF LIPOSOMAL BUPIVACAINE are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nanjing First Hospital
RECRUITINGNanjing, Jiangsu, 210006, China